Litton, J. K., Scoggins, M., Ramirez, D. L., Murthy, R. K., Whitman, G. J., Hess, K. R., . . . Arun, B. K. (2017). A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer.
Παραπομπή Chicago StyleLitton, J. K., et al. "A Feasibility Study of Neoadjuvant Talazoparib for Operable Breast Cancer Patients With a Germline BRCA Mutation Demonstrates Marked Activity." NPJ Breast Cancer 2017.
Παραπομπή MLALitton, J. K., et al. "A Feasibility Study of Neoadjuvant Talazoparib for Operable Breast Cancer Patients With a Germline BRCA Mutation Demonstrates Marked Activity." NPJ Breast Cancer 2017.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.